Page 24 - Read Online

Role of hepatitis B virus precore/core promoter mutations and serum Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P. Risk
viral load on noncirrhotic hepatocellular carcinoma: a case-control and risk factors of hepatocellular carcinoma in Caucasian chronic
study. J Infect Dis 2006;194:594-9. hepatitis B (CHB) patients with or without cirrhosis treated with
9. Orito E, Mizokami M. Hepatitis B virus genotypes and hepatocellular entecavir (ETV) or tenofovir (TDF). Hepatology 2013;58:302A.
carcinoma in Japan. Intervirology 2003;46:408-12. 27. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term
10. Chan HL, Wong ML, Hui AY, Hung LC, Chan FK, Sung JJ. Hepatitis outcome of interferon-alpha treated and untreated patients with
B virus genotype C takes a more aggressive disease course than HBeAg-negative chronic hepatitis B. J Hepatol 2001;34:306-13.
hepatitis B virus genotype B in hepatitis B e antigen-positive patients. 28. Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, Liaw YF.
J Clin Microbiol 2003;41:1277-9. Interferon therapy in HBeAg positive chronic hepatitis reduces
11. Kao JH, Chen PJ, Chen DS. Recent advances in the research of progression to cirrhosis and hepatocellular carcinoma. J Hepatol
hepatitis B virus-related hepatocellular carcinoma: epidemiologic 2007;46:45-52.
and molecular biological aspects. Adv Cancer Res 2010;108:21-72. 29. Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL. Long-
12. Zhang KY, Imazeki F, Fukai K, Arai M, Kanda T, Mikata R, Yokosuka term follow-up of interferon alfa treatment in Chinese patients
O. Analysis of the complete hepatitis B virus genome in patients with chronic hepatitis B infection: the effect on hepatitis B e
with genotype C chronic hepatitis and hepatocellular carcinoma. antigen seroconversion and the development of cirrhosis-related
Cancer Sci 2007;98:1921-9. complications. Hepatology 2001;34:139-45.
13. Zheng JX, Zeng Z, Zheng YY, Yin SJ, Zhang DY, Yu YY, Wang 30. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis:
F. Role of hepatitis B virus base core and precore/core promoter treatment of hepatitis B infection reduces risk of hepatocellular
mutations on hepatocellular carcinoma in untreated older genotype carcinoma. Aliment Pharmacol Ther 2008;28:1067-77.
patients. J Viral Hepat 2011;18:e423-31. 31. Papatheodoridis GV, Manolakopoulos S, Touloumi G, Vourli G,
14. Toh ST, Jin Y, Liu L, Wang J, Babrzadeh F, Gharizadeh B, Ronaghi Raptopoulou-Gigi M, Vafi adis-Zoumbouli I, Vasiliadis T, Mimidis K,
M, Toh HC, Chow PK, Chung AY, Ooi LL, Lee CG. Deep sequencing Gogos C, Ketikoglou I, Manesis EK; HEPNET. Greece Cohort Study
of the hepatitis B virus in hepatocellular carcinoma patients reveals Group. Virological suppression does not prevent the development
enriched integration events, structural alterations and sequence of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B
variations. Carcinogenesis 2013;34:787-98. patients with cirrhosis receiving oral antiviral (s) starting with
15. Bonilla Guerrero R, Roberts LR. The role of hepatitis B virus lamivudine monotherapy: results of the nationwide HEPNET. Greece
integrations in the pathogenesis of human hepatocellular Cohort Study. Gut 2011;60:1109-16.
carcinoma. J Hepatol 2005;42:760-77. 32. Russo FP, Scribano L, RodrÌguez-Castro K, Gottardo G, Vanin
16. Bouchard MJ, Schneider RJ. The enigmatic X gene of hepatitis B V, Farinati F. Impact of therapy on long-term outcome of chronic
virus. J Virol 2004;78:12725-34. hepatitis B. World J Hepatol 2015;18:1097-104.
17. Fattovich G, Bortolotti F, Donato F. Natural history of chronic 33. Abu-Amara M, Feld JJ. Does antiviral therapy for chronic
hepatitis B: special emphasis on disease progression and hepatitis B reduce the risk of hepatocellular carcinoma? Semin
prognostic factors. J Hepatol 2008;48:335-52. Liver Dis 2013;33:157-66.
18. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. 34. Singal AK, Salameh H, Kuo YF, Fontana RJ. Meta-analysis: the
Past HBV viral load as predictor of mortality and morbidity impact of oral anti-viral agents on the incidence of hepatocellular
from HCC and chronic liver disease in a prospective study. Am J carcinoma in chronic hepatitis B. Aliment Pharmacol Ther
Gastroenterol 2006;101:1797-803. 2013;38:98-106.
19. Chen CJ, Yang HI, Iloeje UH; REVEAL-HBV Study Group. 35. Yang SC, Lee CM, Hu TH, Wang JH, Lu SN, Hung CH, Changchien
Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. CS, Chen CH. Virological response to entecavir reduces the risk
Hepatology 2009;49:S72-84. of liver disease progression in nucleos(t)ide analogue-experienced
20. Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, Chan HBV-infected patients with prior resistant mutants. J Antimicrob
HY, Chan FK, Sung JJ, Chan HL. Metabolic syndrome increases the Chemother 2013;68:2154-63.
risk of liver cirrhosis in chronic hepatitis B. Gut 2009;58:111-7. 36. Wong GL, Chan HL, Mak CH, Lee SK, Ip ZM, Lam AT, Iu
21. Chen HP, Shieh JJ, Chang CC, Chen TT, Lin JT, Wu MS, Lin JH, HW, Leung JM, Lai JW, Lo AO, Chan HY, Wong VW. Entecavir
Wu CY. Metformin decreases hepatocellular carcinoma risk in a treatment reduces hepatic events and deaths in chronic hepatitis B
dose-dependent manner: population-based and in vitro studies. Gut patients with liver cirrhosis. Hepatology 2013;58:1537-47.
2013;62:606-15. 37. Kim SS, Ahn SJ, Park SY, Song GW, Cheong JY, Cho SW. Virological
22. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee response to entecavir is associated with low probability of developing
T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J; hepatocellular carcinoma in chronic hepatitis B patients with
Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine cirrhosis. J Hepatol 2013;58:S265.
for patients with chronic hepatitis B and advanced liver disease. 38. Cho JY, Paik YH, Sohn W, Cho HC, Gwak GY, Choi MS, Lee JH,
N Engl J Med 2004;351:1521-31. Koh KC, Paik SW, Yoo BC. Patients with chronic hepatitis B treated
23. Wong VW, Chan SL, Mo F, Chan TC, Loong HH, Wong GL, Lui YY, with oral antiviral therapy retain a higher risk for HCC compared
Chan AT, Sung JJ, Yeo W, Chan HL, Mok TS. Clinical scoring system with patients with inactive stage disease. Gut 2014;63:1943-50.
to predict hepatocellular carcinoma in chronic hepatitis B carriers. J 39. European Association for the Study of the Liver. EASL clinical
Clin Oncol 2010;28:1660-5. practice guidelines: management of chronic hepatitis B virus
24. Yuen MF, Tanaka Y, Fong DY, Fung J, Wong DK, Yuen JC, But DY, infection. J Hepatol 2012;57:167-85.
Chan AO, Wong BC, Mizokami M, Lai CL. Independent risk factors 40. Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane
and predictive score for the development of hepatocellular carcinoma E, Locarnini S, Lim SG, Han KH, Amarapurkar D, Cooksley G,
in chronic hepatitis B. J Hepatol 2009;50:80-8. Jafri W, Mohamed R, Hou JL, Chuang WL, Lesmana LA, Sollano
25. Yang HI, Yuen MF, Chan HL, Han KH, Chen PJ, Kim DY, Ahn SH, JD, Suh DJ, Omata M. Asian-pacfic consensus statement on the
Chen CJ, Wong VW, Seto WK; REACH-B Working Group. management of chronic hepatitis B: a 2012 update. Hepatol Int
Risk estimation for hepatocellular carcinoma in chronic hepatitis 2012;6:531-61.
B (REACH-B): development and validation of a predictive score. 41. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology
Lancet Oncol 2011;12:568-74. 2009;50:661-2.
26. Papatheodoridis GV, Dalekos GN, Yurdaydin C, Buti M, Goulis 42. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki
J, Arends P, Sypsa V, Manolakopoulos S, Mangia G, Gatselis N, H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M,
Keskın O, Savvidou S, Hansen BE, Papaioannou C, Galanis K, Kumada H. Long-term entecavir treatment reduces hepatocellular

Hepatoma Research | Volume 2 | Issue 1 | January 15, 2016 15